NHS Framework Agreement for Branded Pharmaceuticals - North of England Tranche A.
The value below is a framework or dynamic market ceiling: the maximum
that could be spent across all call-offs, not the value of a single contract.
Aggregate figures on this site exclude these to avoid double counting.
key details
| Value | £575,675,600 |
|---|---|
| Status | complete |
| Category (CPV) | 33600000 |
| Region | North East, North West, Yorkshire and the Humber |
| Deadline | 6 Oct 2016 |
| Contract start | 1 Mar 2017 |
| Contract end | 28 Feb 2019 |
| Procedure | open |
| SME suitable | No |
| OCID | ocds-b5fd17-b1cc7c24-7de7-4eda-93c6-14fb3947df83 |
Award
| Supplier | Value | Date | Status |
|---|---|---|---|
| Please refer to award schedules for awarded suppliers | £0 | 8 Feb 2017 | active |
description
Branded North of England Branded Medicines - Tranche A - March 2017
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 24 Apr 2017 | Award (award) | · | ae3878fa-6ba3-4ac9-98ed-bf0becc6afa7-143407 |
more from COMMERCIAL MEDICINES UNIT
- NHS Framework Agreement for the Midlands and East Pharmacy Purchasing Group for the supply of Proprietary Pharmaceuticals - Tranche B · £102,379,487 · 24 Apr 2017
- Contract for the supply of BCG vaccine · 9 Jan 2017
- Contract for the supply of human papillomavrius vaccine · 22 Dec 2016
- NHS National Pharmaceuticals - Wave 10c Offer reference number: CM/PHG/15/5466 Period of framework agreement: Dates detailed below with options to extend up to a maximum period of 40 months. Potential periods of call-offs under the framework agreement: Oral Products: All Regions 01/07/2017 to 28/02/2019 (20 months) Hospital Only Products: Central and South West (CESW) 01/07/2017 to 30/06/2018 (12 months); North West and Eastern and North London (NWLN) 01/07/2017 to 30/06/2018 (12 months) and South East and South London and North East and Yorkshire (LSNE) 01/07/2017 to 30/06/2018 (12 months) · £182,500,000 · 16 Dec 2016
- NHS Framework Agreement for Hepatitis C Medicines for Midlands and East and North of England regions · £85,000,000 · 25 Nov 2016
- Invitation to offer for NHS Framework Agreement for Branded Pharmaceuticals for London – Tranche A (inc. Hepatitis C) · £201,544,684 · 18 Nov 2016
- Contract for the supply of BCG vaccine · 18 Nov 2016
- NHS Framework Agreement for Proprietary Pharmaceuticals - Interim 2016_1 · £225,000,000 · 18 Nov 2016
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.